ProShare Advisors
DNA icon

ProShare Advisors’s Ginkgo Bioworks DNA Stock Holding History

ProShare Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Buy
+12,472
New +$104K ﹤0.01% 1745
2023
Q2 		– Sell
-393
Closed -$20.9K – 1863
2023
Q1 		$20.9K Sell
393
-592
-60% -$37.5K ﹤0.01% 1733
2022
Q4 		$66.6K Buy
985
+116
+13% +$10.7K ﹤0.01% 1706
2022
Q3 		$108K Sell
869
-313
-26% -$37.3K ﹤0.01% 1545
2022
Q2 		$112K Sell
1,182
-577
-33% -$70.4K ﹤0.01% 1594
2022
Q1 		$284K Buy
+1,759
New +$342K ﹤0.01% 1662

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

ProShare Advisors's DNA Position: Q2 2026 in Review

ProShare Advisors opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 12,472 shares worth $124K. The stake represents ﹤0.01% of the portfolio and ranks #1745 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in DNA as recently as Q1 2023.

ProShare Advisors first reported a position in DNA in Q1 2022 and has held it in 6 quarters since. The position peaked at $284K in Q1 2022. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • ProShare Advisors held 12,472 shares of Ginkgo Bioworks worth $124K as of Q2 2026.
  • Ginkgo Bioworks was a new ProShare Advisors position in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1745 holding.
  • ProShare Advisors first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 6 quarters since.
  • ProShare Advisors's Ginkgo Bioworks position peaked at $284K in Q1 2022.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.